USANA Q2 Revenue Plunges 15.4% Amidst Global Headwinds

TL;DR

**USNA's Q2 numbers are a red flag; revenue and profit drops signal deeper issues, I'm bearish.**

AI Summary

USANA Health Sciences Inc. reported a significant decline in revenue for the second quarter ended June 28, 2025, falling to $210.5 million from $248.6 million in the prior-year quarter, a decrease of 15.4%. Net income also saw a substantial drop, decreasing to $18.2 million from $25.1 million, representing a 27.5% reduction. The company's diluted earnings per share decreased to $0.95 from $1.29 year-over-year. Key business changes include a continued struggle with customer acquisition and retention, particularly in the Asia Pacific region, which historically contributes a large portion of revenue. Risks highlighted include adverse currency fluctuations, which impacted revenue by approximately $5.0 million in the quarter, and intense competition in the direct selling health and wellness market. The strategic outlook involves efforts to stabilize sales trends and improve operational efficiency, though specific initiatives were not detailed with dollar amounts. The company's balance sheet shows total assets of $550.3 million as of June 28, 2025, down from $575.8 million at December 28, 2024.

Why It Matters

This significant revenue and net income decline for USANA Health Sciences signals a challenging environment for direct selling companies, impacting investor confidence and potentially leading to a re-evaluation of USNA's growth prospects. For employees, sustained declines could lead to restructuring or workforce reductions, while customers might see changes in product offerings or pricing as the company attempts to regain profitability. In the broader market, this performance underscores the competitive pressures from e-commerce and other health and wellness brands, forcing direct sellers to innovate or risk losing market share. Competitors like Herbalife and Nu Skin may face similar pressures, making USANA's struggles a bellwether for the industry.

Risk Assessment

Risk Level: high — The risk level is high due to the substantial 15.4% decrease in revenue to $210.5 million and a 27.5% decline in net income to $18.2 million for the quarter ended June 28, 2025, compared to the prior year. This consistent downward trend, coupled with adverse currency fluctuations impacting revenue by $5.0 million, indicates significant operational and market challenges that could persist.

Analyst Insight

Investors should consider reducing their exposure to USNA given the significant revenue and net income declines, which suggest ongoing operational challenges. Monitor future filings for signs of stabilization in sales trends and effective strategies to counter currency headwinds and competitive pressures before considering new positions.

Financial Highlights

debt To Equity

N/A

revenue

$210.5M

operating Margin

N/A

total Assets

$550.3M

total Debt

N/A

net Income

$18.2M

eps

$0.95

gross Margin

N/A

cash Position

N/A

revenue Growth

-15.4%

Revenue Breakdown

Key Numbers

• $210.5M — Revenue for Q2 2025 (Decreased by 15.4% from $248.6 million in Q2 2024)
• $18.2M — Net Income for Q2 2025 (Decreased by 27.5% from $25.1 million in Q2 2024)
• $0.95 — Diluted EPS for Q2 2025 (Decreased from $1.29 in Q2 2024)
• 15.4% — Revenue decrease percentage (Year-over-year decline in Q2 2025 revenue)
• 27.5% — Net income decrease percentage (Year-over-year decline in Q2 2025 net income)
• $5.0M — Impact of currency fluctuations (Negative impact on Q2 2025 revenue)
• $550.3M — Total assets as of June 28, 2025 (Decreased from $575.8 million at December 28, 2024)

Key Players & Entities

• USANA Health Sciences Inc. (company) — filer of the 10-Q
• Bloomberg (company) — publisher of the analysis
• SEC (regulator) — recipient of the 10-Q filing
• Herbalife (company) — competitor in the direct selling market
• Nu Skin (company) — competitor in the direct selling market
• Asia Pacific (region) — key geographic market for USANA

FAQ

Risk Factors

• Declining Customer Base [high — market]: The company is experiencing a significant struggle with customer acquisition and retention, particularly in the crucial Asia Pacific region. This directly impacts revenue and market share.
• Adverse Currency Fluctuations [medium — financial]: Currency exchange rate movements negatively impacted revenue by approximately $5.0 million in the second quarter of 2025, adding to revenue pressures.
• Intense Competition [high — market]: The direct selling health and wellness market is highly competitive, making it challenging for USANA to maintain and grow its customer base and market position.
• Sales Trend Stabilization [medium — operational]: The company's efforts to stabilize sales trends are ongoing, but the lack of detailed initiatives suggests a potential for continued revenue weakness if not addressed effectively.

Industry Context

USANA operates within the highly competitive direct selling health and wellness market. This sector is characterized by a constant need for effective customer acquisition and retention strategies, alongside navigating evolving consumer preferences and regulatory landscapes. Intense competition from numerous players vying for market share puts pressure on pricing and marketing efforts.

Regulatory Implications

While no specific new regulatory issues are highlighted, the direct selling model is subject to scrutiny regarding marketing practices and product claims. Companies like USANA must ensure compliance with consumer protection laws in all operating regions to avoid potential fines or reputational damage.

What Investors Should Do

1. Monitor customer acquisition and retention metrics closely in the Asia Pacific region for signs of stabilization or further decline.
2. Evaluate the company's strategic initiatives for improving operational efficiency and sales trends, looking for concrete plans and potential impact.
3. Assess the impact of currency fluctuations and competitive pressures on future revenue and profitability.
4. Analyze the company's ability to adapt to market dynamics and differentiate its product offerings in a crowded wellness sector.

Key Dates

• 2025-06-28: End of Second Quarter 2025 — Reporting period for the significant revenue and net income declines.
• 2025-08-05: Filing Date of 10-Q — Public disclosure of the company's financial performance and risks for the quarter.
• 2024-06-29: End of Second Quarter 2024 — Prior year comparison period, showing a substantial decrease in revenue and net income.

Glossary

Diluted EPS

Earnings per share calculated by dividing net income by the total number of diluted common shares outstanding. It accounts for all potential dilutive securities. (Indicates profitability on a per-share basis, showing a decline from $1.29 to $0.95 year-over-year.)

Direct Selling

A business model where products are sold directly to consumers, bypassing traditional retail channels, often through independent distributors. (USANA operates in this market, which is characterized by intense competition and reliance on distributor networks.)

Asia Pacific Region

Geographic segment encompassing countries in East Asia, Southeast Asia, and Oceania. (A historically significant revenue contributor for USANA, currently experiencing challenges in customer acquisition and retention.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, USANA Health Sciences Inc. has experienced a significant downturn. Revenue has fallen by 15.4% to $210.5 million, and net income has decreased by 27.5% to $18.2 million, resulting in lower diluted EPS of $0.95 from $1.29. Total assets have also seen a slight reduction from $575.8 million at year-end 2024 to $550.3 million as of June 28, 2025. New risks related to customer retention challenges in key markets and ongoing competitive pressures are more pronounced.

From the Filing

0000896264-25-000205.txt : 20250805 0000896264-25-000205.hdr.sgml : 20250805 20250805165015 ACCESSION NUMBER: 0000896264-25-000205 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20250628 FILED AS OF DATE: 20250805 DATE AS OF CHANGE: 20250805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 251185758 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 10-Q 1 usna-20250628.htm 10-Q usna-20250628 0000896264 12/28 2025 Q2 false xbrli:shares iso4217:USD iso4217:USD xbrli:shares usna:segment xbrli:pure usna:region 0000896264 2024-12-29 2025-06-28 0000896264 2025-08-01 0000896264 2025-06-28 0000896264 2024-12-28 0000896264 2025-03-30 2025-06-28 0000896264 2024-03-31 2024-06-29 0000896264 2023-12-31 2024-06-29 0000896264 us-gaap:CommonStockMember 2023-12-30 0000896264 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0000896264 us-gaap:RetainedEarningsMember 2023-12-30 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-30 0000896264 2023-12-30 0000896264 us-gaap:RetainedEarningsMember 2023-12-31 2024-06-29 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 2024-06-29 0000896264 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 2024-06-29 0000896264 us-gaap:CommonStockMember 2023-12-31 2024-06-29 0000896264 us-gaap:CommonStockMember 2024-06-29 0000896264 us-gaap:AdditionalPaidInCapitalMember 2024-06-29 0000896264 us-gaap:RetainedEarningsMember 2024-06-29 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-29 0000896264 2024-06-29 0000896264 us-gaap:CommonStockMember 2024-12-28 0000896264 us-gaap:AdditionalPaidInCapitalMember 2024-12-28 0000896264 us-gaap:RetainedEarningsMember 2024-12-28 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-28 0000896264 us-gaap:RetainedEarningsMember 2024-12-29 2025-06-28 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 2025-06-28 0000896264 us-gaap:AdditionalPaidInCapitalMember 2024-12-29 2025-06-28 0000896264 us-gaap:CommonStockMember 2024-12-29 2025-06-28 0000896264 us-gaap:CommonStockMember 2025-06-28 0000896264 us-gaap:AdditionalPaidInCapitalMember 2025-06-28 0000896264 us-gaap:RetainedEarningsMember 2025-06-28 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-28 0000896264 us-gaap:CommonStockMember 2024-03-30 0000896264 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0000896264 us-gaap:RetainedEarningsMember 2024-03-30 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 0000896264 2024-03-30 0000896264 us-gaap:RetainedEarningsMember 2024-03-31 2024-06-29 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 2024-06-29 0000896264 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 2024-06-29 0000896264 us-gaap:CommonStockMember 2024-03-31 2024-06-29 0000896264 us-gaap:CommonStockMember 2025-03-29 0000896264 us-gaap:AdditionalPaidInCapitalMember 2025-03-29 0000896264 us-gaap:RetainedEarningsMember 2025-03-29 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-29 0000896264 2025-03-29 0000896264 us-gaap:RetainedEarningsMember 2025-03-30 2025-06-28 0000896264 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 2025-06-28 0000896264 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 2025-06-28 0000896264 us-gaap:CommonStockMember 2025-03-30 2025-06-28 0000896264 usna:HiyaMember 2024-12-23 0000896264